NIKKEI 225
32,371.90 +56.85 (+0.18%) HANG SENG
17,611.87 +144.97 (+0.83%) CRUDE OIL
93.79 +3.40 (+3.76%) GOLD FUTURES
1,894.70 -25.10 (-1.31%) DOW
33,452.07 -166.81 (-0.50%) Bitcoin GBP
21,676.80 +31.28 (+0.14%)
Valneva SE (0OB3.L)
| Previous close | 5.60 |
| Open | 5.58 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.52 - 5.70 |
| 52-week range | 3.96 - 7.84 |
| Volume | |
| Avg. volume | 35,651 |
| Market cap | 4.96M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireValneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive
- Globe Newswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023 Strong cash position of €204.4 million as at June 30, 2023 Excludes up to an additional $100 million made available as part of a recent upsized financing arrangemen
- Globe Newswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15 well-tolerated in all age groups following booster dose Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine ca
